INTRABIOTICS PHARMACEUTICALS INC /DE Form 8-K

June 24, 2004

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

# Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2004

#### IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

0-29993	94-3200380
(Commission File Number)	(IRS Employer Identification No.)
	(Commission

## 2483 East Bayshore Road, Suite 100 Palo Alto, California 94303

(Address of principal executive offices and zip code)

Registrant s telephone number, including area code: (650) 526-6800

### **Not Applicable**

(Former name or former address, if changed since last report.)

## **TABLE OF CONTENTS**

Item 5. Other Events.

Item 7. Financial Statements and Exhibits.

**SIGNATURE** 

**INDEX TO EXHIBITS** 

**EXHIBIT 99.1** 

#### **Table of Contents**

Item 5. Other Events.

On June 23, 2004, IntraBiotics Pharmaceuticals, Inc. announced that it had stopped its iseganan trial in ventilator-associated pneumonia for safety reasons. A copy of the related press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

### Item 7. Financial Statements and Exhibits.

- (c) Exhibits. The following documents are filed as exhibits to this report:
  - 99.1 Press Release, dated June 23, 2004, entitled IntraBiotics Stopped Iseganan Trial in Ventilator-Associated Pneumonia for Safety Reasons.

#### **Table of Contents**

### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTRABIOTICS PHARMACEUTICALS, INC.

Date: June 24, 2004 /s/ David Tucker
David Tucker

Principal Financial Officer

## **Table of Contents**

### **INDEX TO EXHIBITS**

99.1 Press Release, dated June 23, 2004, entitled IntraBiotics Stopped Iseganan Trial in Ventilator-Associated Pneumonia for Safety Reasons.